GLUE (Monte Rosa Therapeutics Inc) Earnings per share for the last four quarters

Public company logo of Monte Rosa Therapeutics Inc (GLUE)

The price action of Monte Rosa Therapeutics (GLUE) reflects EPS figures at -599.30. The firm's financial stability is supported by substantial payments from Roche. A proprietary protein degradation method for creating global products provides high growth potential. However, the company is currently spending all its capital on early-stage testing, meaning market pricing for the drugs will only be possible after their efficacy is confirmed.

GLUE monterosatx.com Earnings per share for the last twelve months (02/11/2024 - 11/11/2026)

Monte Rosa Tx - analytical breakdowns and key metrics (GLUE)

- current price and projected stock value:
Price Performance Chart monterosatx.com|GLUE - Consensus Target
- business market valuation indicators:
Market Value Monte Rosa Therapeutics Inc|GLUE - Enterprise Value
- business book valuation details:
Book Value per Share Monte Rosa Therapeutics|GLUE - Company Book Value|Market Value to Book Value monterosatx.com|GLUE - Company Total Assets
- company total debt and liquidity indicators:
Debt to Capital Ratio Monte Rosa Therapeutics|GLUE - Long-Term Debt to Capital|Current Liabilities to Capital Monte Rosa Corp|GLUE - Company Total Debt|Debt to Book Capital Monte Rosa Therapeutics Inc|GLUE - Company Long-Term Debts|Short-Term Debt Monte Rosa Therapeutics|Immediate Liquidity Ratio monterosatx.com
- earnings and multiples data:
GLUE - Net Income|Expected Net Income Monte Rosa Therapeutics|GLUE - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Monte Rosa Therapeutics Inc|GLUE - PEG Multiple|Business Value to Operating Income Before Depreciation Monte Rosa Therapeutics Inc|GLUE - Operating profit EBITDA|Net earnings per one share for the last twelve months Monte Rosa Therapeutics|GLUE - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months monterosatx.com|GLUE - Earnings growth in current year|Earnings growth forecast for next year Monte Rosa Therapeutics
Fundamental valuation:monterosatx.com (GLUE)
Signature product of Monte Rosa Therapeutics, Inc.

The market assesses Monte Rosa Therapeutics (GLUE) as a high-risk asset with potential for breakthrough growth. This metric measures the trailing twelve months (TTM) earnings per share dynamics, updating the consensus daily to identify hidden trend reversals. By analyzing the annual growth trend of TTM net income per share, investors align financial expectations with the successes of the protein degradation platform. This biotech startup is classified as a speculative security.

Competitor analysis for Monte Rosa Therapeutics

Earnings per share for the trailing year GMAB (genmab.com)|EXEL (Exelixis) - Net earnings per share for the last 12 months|NUVL: Earnings per share for the last four quarters|KYMR (Kymera Therapeutics Inc) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) IDEAYA Corp|Earnings per share for the last twelve months Enliven Therapeutics (ELVN)|ORIC (oricpharma.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) RLAY (Relay Therapeutics, Inc.)|Net earnings per share for the trailing year Nurix Therapeutics Inc|Tyra Bio - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Verastem Corp|CGEM (Cullinan Therapeutics) - Net earnings per share for the last 12 months|IMRX: Earnings per share for the last four quarters|CCCC (C4 Therapeutics) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Black Diamond Therapeutics, Inc. BDTX|Net earnings per share (EPS TTM) RPTX|PMV Pharmaceuticals, Inc - Earnings per share for the last 12 months|Karyopharm Therapeutics Inc. - Net earnings per share for the last 12 months|Earnings per share for the trailing year PPCB|BGMS: Net earnings per share for the last 12 months|Aadi Bioscience - Earnings per share for the last four quarters|ALRN: Net earnings per share (EPS TTM)|Blueprint Medicines Corporation - Earnings per share for the trailing year|GLYC (GlycoMimetics Inc.) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months springworkstx.com SWTX